Summit Therapeutics Inc. (SMMT)
| Market Cap | 12.90B -29.5% |
| Revenue (ttm) | n/a |
| Net Income | -1.21B |
| EPS | -1.59 |
| Shares Out | 776.16M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,890,997 |
| Open | 16.48 |
| Previous Close | 17.47 |
| Day's Range | 16.13 - 17.40 |
| 52-Week Range | 13.83 - 30.98 |
| Beta | -1.26 |
| Analysts | Buy |
| Price Target | 28.50 (+71.48%) |
| Earnings Date | Apr 30, 2026 |
About SMMT
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth facto... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for SMMT stock is "Buy." The 12-month stock price target is $28.5, which is an increase of 71.48% from the latest price.
News
Summit Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Summit Therapeutics (SMMT) to Neutral from Buy without a price target The firm is concerned by the continued absence of a more mature HARMONi-2 OS update. Without…
Bernstein starts Summit with an Underperform, says ‘not on solid footing’
Bernstein analyst Jeffrey Walch initiated coverage of Summit Therapeutics (SMMT) with an Underperform rating and $7.70 price target The firm recommended investors “exit positions or, if possible, init...
Summit Therapeutics initiated with an Underperform at Bernstein
Bernstein initiated coverage of Summit Therapeutics (SMMT) with an Underperform rating and $7.70 price target
3 Best Stocks to Buy This Week, According to Analysts – May 18-May 22
Three names are expected to have strong setups this week: Zeta Global ($ZETA), Boston Scientific ($BSX), and Summit Therapeutics ($SMMT). Each stock has its own catalyst, and analysts see room…
Summit Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Summit Therapeutics Inc. (NASDAQ: SMMT). The investigation focuses on Summi...
Summit Therapeutics price target lowered to $23 from $30 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Summit Therapeutics (SMMT) to $23 from $30 and keeps a Buy rating on the shares. The firm says the absence of a…
Summit Therapeutics falls -23.7%
Summit Therapeutics (SMMT) is down -23.7%, or -$5.08 to $16.38.
Summit Therapeutics falls -27.4%
Summit Therapeutics (SMMT) is down -27.4%, or -$5.88 to $15.58.
Summit Therapeutics price target lowered to $16 from $17 at Piper Sandler
Piper Sandler lowered the firm’s price target on Summit Therapeutics (SMMT) to $16 from $17 and keeps a Neutral rating on the shares. The firm notes the company reported Q1…
Summit Therapeutics price target lowered to $31 from $32 at Clear Street
Clear Street lowered the firm’s price target on Summit Therapeutics (SMMT) to $31 from $32 and keeps a Buy rating on the shares. An interim PFS analysis was performed on…
Summit Therapeutics reports Q1 adjusted EPS (15c), consensus (21c)
Operational progress continues with ivonescimab (SMT112), an investigational, potentially first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti...
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on clinical and operational prog...
Summit Therapeutics Earnings release: Q1 2026
Summit Therapeutics released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Summit Therapeutics Quarterly report: Q1 2026
Summit Therapeutics has published its Q1 2026 quarterly earnings report on April 30, 2026.
Summit Therapeutics options imply 7.3% move in share price post-earnings
Pre-earnings options volume in Summit Therapeutics (SMMT) is normal with calls leading puts 9:2. Implied volatility suggests the market is anticipating a move near 7.3%, or $1.59, after results are…
Summit Therapeutics put volume heavy and directionally bearish
Bearish flow noted in Summit Therapeutics (SMMT) with 5,713 puts trading, or 14x expected. Most active are Jul-26 20 puts and Jun-26 23 puts, with total volume in those strikes…
Summit partner selection for ASCO plenary signals strong OS, says Leerink
Leerink analyst Daina Graybosch notes that HARMONi-06 overall survival analysis from Akeso and partner Summit Therapeutics (SMMT) was selected as one of five plenary presentations at the ASCO annual m...
Summit partner selection for ASCO ‘likely a major positive,’ says Guggenheim
Guggenheim contends that investors “should be positively surprised” to see Summit Therapeutics (SMMT)’ partner Akeso’s first disclosure for HARMONi-6 data selected for the ASCO plenary session. Many f...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Summit Therapeutics (SMMT), 173.61% surge in interest CG ...
Summit Therapeutics Proxy statement: Proxy filing
Summit Therapeutics filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Summit Therapeutics Proxy statement: Proxy filing
Summit Therapeutics filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Summit Therapeutics Proxy statement: Proxy filing
Summit Therapeutics filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecifi...
Summit Therapeutics Transcript: The Citizens Life Sciences Conference 2026
Ivonescimab has shown strong efficacy and tolerability in multiple phase 3 studies, outperforming PD-1 inhibitors in both monotherapy and combination settings. Key regulatory milestones are set for 2026, with broad expansion plans across major solid tumor indications.
Summit Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
The session highlighted the global expansion of ivonescimab through multiple late-stage studies, regulatory progress with a 2026 PDUFA date, and strong efficacy and safety data across regions. Upcoming milestones include interim and final analyses in lung and colorectal cancer, with further studies planned.